Literature DB >> 11924651

Genetic susceptibility in Dupuytren's disease. TGF-beta1 polymorphisms and Dupuytren's disease.

A Bayat1, J S Watson, J K Stanley, A Alansari, M Shah, M W J Ferguson, W E R Ollier.   

Abstract

Dupuytren's disease is a benign fibroproliferative disease of unknown aetiology. It is often familial and commonly affects Northern European Caucasian men, but genetic studies have yet to identify the relevant genes. Transforming growth factor beta one (TGF-beta1) is a multifunctional cytokine which plays a central role in wound healing and fibrosis. It stimulates the proliferation of fibroblasts and the deposition of extracellular matrix. Previous studies have implicated TGF-beta1 in Dupuytren's disease, suggesting that it may represent a candidate susceptibility gene for this condition. We have investigated the association of four common single nucleotide polymorphisms in TGF-beta1 with the risk of developing Dupuytren's disease. A polymerase chain reaction-restriction fragment length polymorphism method was used for genotyping TGF-beta1 polymorphisms. DNA samples from 135 patients with Dupuytren's disease and 200 control subjects were examined. There was no statistically significant difference in TGF-beta1 genotype or allele frequency distributions between the patients and controls for the codons 10, 25, -509 and -800 polymorphisms. Our observations suggest that common TGF-beta1 polymorphisms are not associated with a risk of developing Dupuytren's disease. These data should be interpreted with caution since the lack of association was shown in only one series of patients with only known, common polymorphisms of TGF-beta1. To our knowledge, this is the first report of a case-control association study in Dupuytren's disease using single nucleotide polymorphisms in TGF-beta1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924651     DOI: 10.1302/0301-620x.84b2.12083

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  6 in total

1.  Dupuytren's contracture following burn injury of the hand: A case report and review of literature.

Authors:  Chenicheri Balakrishnan; Kristoffer B Sugg; William Huettner; Payam Jarrahnejad
Journal:  Can J Plast Surg       Date:  2008

2.  Role of the HLA System in the Pathogenesis of Dupuytren's Disease.

Authors:  Sara McCarty; Farhatullah Syed; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2010-02-09

3.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

Review 4.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

5.  The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.

Authors:  Alexis Thomas; Ardeshir Bayat
Journal:  Ther Clin Risk Manag       Date:  2010-11-04       Impact factor: 2.423

6.  In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.

Authors:  Farhatullah Syed; Alexis N Thomas; Subir Singh; Venkatesh Kolluru; Susan G Emeigh Hart; Ardeshir Bayat
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.